Quantitative immunoassay to measure plasma and intracellular atazanavir levels: Analysis of drug accumulation in cultured T cells

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 2, 2007, Pages 405-411

  Roucairol, Camille ^a   Azoulay, Stéphane ^a   Nevers, Marie Claire ^b   Créminon, Christophe ^b   Lavrut, Thibault ^c   Garraffo, Rodolphe ^c   Grassi, Jacques ^b   Burger, Alain ^a   Duval, Danièle ^a  

^a UNIVERSITÉ CÔTE D'AZUR   (France)

^b Institut National de la Recherche Agronomique   (France)

^c PASTEUR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; ANTIGEN; ATAZANAVIR; BOVINE SERUM ALBUMIN; DIPYRIDAMOLE; GLYCOPROTEIN P; NEVIRAPINE; POLYCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; ENZYME IMMUNOASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MICROTITER PLATE ASSAY; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ASSAY; SENSITIVITY AND SPECIFICITY; T LYMPHOCYTE; VALIDATION PROCESS;

ANIMALS; ANTIBODIES; CATTLE; CELLS, CULTURED; DIPYRIDAMOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV PROTEASE INHIBITORS; HUMANS; IMMUNOASSAY; OLIGOPEPTIDES; P-GLYCOPROTEIN; PHOSPHODIESTERASE INHIBITORS; PYRIDINES; RABBITS; SENSITIVITY AND SPECIFICITY; T-LYMPHOCYTES;

EID: 33846621932     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00730-06     Document Type: Article

References (28)

1. Almond, L. M., D. Edirisinghe, M. Dalton, A. Bonington, D. J. Back, and S. H. Khoo. 2005. Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals. Clin. Pharmacol. Ther. 78:132-142.
2. Almond, L. M., P. G. Hoggard, D. Edirisinghe, S. H. Khoo, and D. J. Back. 2005. Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals. J. Antimicrob. Chemother. 56:738-744.
3. Azoulay, S., M. C. Nevers, C. Creminon, L. Heripret, J. Durant, P. Dellamonica, J. Grassi, R. Guedj, and D. Duval. 2004. Sensitive enzyme immunoassay for measuring plasma and intracellular nevirapine levels in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 48:104-109.
4. Childs, S., and V. Ling. 1994. The MDR superfamily of genes and its biological implications, p. 21-36. Important Adv. Oncol.
5. Colombo, S., A. Beguin, A. Telenti, J. Biollaz, T. Buclin, B. Rochat, and L. A. Decosterd. 2005. Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 819:259-276.
6. Colombo, S., N. Guignard, C. Marzolini, A. Telenti, J. Biollaz, and L. A. Decosterd. 2004. Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solid-phase extraction. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 810:25-34.
7. Dailly, E., F. Raffi, and P. Jolliet. 2004. Determination of atazanavir and other antiretroviral drugs (indinavir, amprenavir, nelfinavir and its active metabolite M8, saquinavir, ritonavir, lopinavir, nevirapine and efavirenz) plasma levels by high performance liquid chromatography with UV detection. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 813:353-358.
8. Dickinson, L., L. Robinson, J. Tjia, S. Khoo, and D. Back. 2005. Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 829:82-90.
9. Ford, J., S. H. Khoo, and D. J. Back. 2004. The intracellular pharmacology of antiretroviral protease inhibitors. J. Antimicrob. Chemother. 54:982-990.
10. Gollapudi, S., C. H. Kim, B. N. Tran, S. Sangha, and S. Gupta. 1997. Probenecid reverses multidrug resistance in multidrug resistance- associated protein-overexpressing HL60/AR and H69/AR cells but not in P-glycoprotein-overexpressing HL60/Tax and P388/ADR cells. Cancer Chemother. Pharmacol. 40:150-158.
11. Jemal, M., S. Rao, M. Gatz, and D. Whigan. 2003. Liquid chromatography-tandem mass spectrometric quantitative determination of the HIV protease inhibitor atazanavir (BMS-232632) in human peripheral blood mononuclear cells (PBMC): practical approaches to PBMC preparation and PBMC assay design for high-throughput analysis. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 795:273-289.
12. Kim, R. B. 2003. Drug transporters in HIV therapy. Top. HIV Med. 11:136-139.
13. Krishan, A., K. S. Sridhar, C. Mou, W. D. Stein, E. Lyubimov, Y. P. Hu, and H. Fernandez. 2000. Synergistic effect of prochlorperazine and dipyridamole on the cellular retention and cytotoxicity of doxorubicin. Clin. Cancer Res. 6:1508-1517.
14. Ledergerber, B., M. Egger, M. Opravil, A. Telenti, B. Hirschel, M. Battegay, P. Vernazza, P. Sudre, M. Flepp, H. Furrer, P. Francioli, R. Weber, et al. 1999. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 353:863-868.
15. Loo, T. W., and D. M. Clarke. 2005. Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux. J. Membr. Biol. 206:173-185.
16. Lucia, M. B., C. Golotta, S. Rutella, E. Rastrelli, A. Savarino, and R. Cauda. 2005. Atazanavir inhibits P-glycoprotein and multidrug resistance-associated protein efflux activity. J. Acquir. Immune Defic. Syndr. 39:635-637.
17. Nolan, D. 2003. Metabolic complications associated with HIV protease inhibitor therapy. Drugs 63:2555-2574.
18. Notari, S., A. Bocedi, G. Ippolito, P. Narciso, L. P. Pucillo, G. Tossini, R. P. Donnorso, F. Gasparrini, and P. Ascenzi. 2006. Simultaneous determination of 16 anti-HIV drugs in human plasma by high-performance liquid chromatography. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 831:258-266.
19. Olson, D. P., D. T. Scadden, R. T. D'Aquila, and M. P. De Pasquale. 2002. The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1). AIDS 16:1743-1747.
20. Perloff, E. S., S. X. Duan, P. R. Skolnik, D. J. Greenblatt, and L. L. von Moltke. 2005. Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab. Dispos. 33:764-770.
21. Schuster, A., S. Burzawa, M. Jemal, E. Loizillon, P. Couerbe, and D. Whigan. 2003. Quantitative determination of the HIV protease inhibitor atazanavir (BMS-232632) in human plasma by liquid chromatography-tandem mass spectrometry following automated solid-phase extraction. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 788:377-386.
22. Soh, C. H., J. M. Oleske, M. T. Brady, S. A. Spector, W. Borkowsky, S. K. Burchett, M. D. Foca, E. Handelsman, E. Jimenez, W. M. Dankner, and M. D. Hughes. 2003. Long-term effects of protease-inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents. Lancet 362:2045-2051.
23. Stormer, E., L. L. von Moltke, M. D. Perloff, and D. J. Greenblatt. 2002. Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm. Res. 19:1038-1045.
24. Su, Y., X. Zhang, and P. J. Sinko. 2004. Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of saquinavir in Hep G2 cells. Mol. Pharm. 1:49-56.
25. Tribut, O., M. C. Verdier, C. Arvieux, H. Allain, C. Michelet, and D. Bentue-Ferrer. 2005. Simultaneous quantitative assay of atazanavir and 6 other HIV protease inhibitors by isocratic reversed-phase liquid chromatography in human plasma. Ther. Drug Monit. 27:265-269.
26. Van der Sandt, I., C. M. Vos, L. Nabulsi, M. C. Blom-Roosemalen, H. H. Voorwinden, A. G. de Boer, and D. D. Breimer. 2001. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood-brain barrier. AIDS 15:483-491.
27. Verstuyft, C., S. Strabach, H. El Morabet, R. Kerb, U. Brinkmann, L. Dubert, P. Jaillon, C. Funck-Brentano, G. Trugnan, and L. Becquemont. 2003. Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition. Clin. Pharmacol. Ther. 73:51-60.
28. + monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy. J. Virol. 76:707-716.